X4 Pharmaceuticals Submitted a Marketing Application To The FDA For The Approval Of Once-daily, Oral Mavorixafor For Individuals Aged 12 And Older With WHIM (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) Syndrome, A Rare Immunodeficiency
Benzinga Newsdesk - Sep 5, 2023, 8:04AM